Status:
UNKNOWN
Target Attainment of Cefuroxim
Lead Sponsor:
Noordwest Ziekenhuisgroep
Conditions:
Infection, Bacterial
Kinesics
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
SUMMARY Rationale: Optimal antibiotic dosing in patients with bacterial infections is of high importance. Underdosing can lead to treatment failure and can promote emergence of antimicrobial resistanc...
Eligibility Criteria
Inclusion
- Receiving cefuroxime therapy intravenous (iv) as part of standard care
- Age ≥ 18 years
- Admitted to a general ward of Noordwest Ziekenhuisgroep - location Alkmaar
- Informed consent is obtained
Exclusion
- Mentally incapacitated patients, i.e. a minor or legally incompetent adult
- Renal replacement therapy during treatment with cefuroxime
- Patients admitted to the intensive care unit (ICU)
- Severely burned patients, defined as a burned surface ≥ 10%
- Patients with cystic fibrosis
- Informed consent is not obtained
Key Trial Info
Start Date :
January 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05200975
Start Date
January 15 2022
End Date
January 1 2023
Last Update
April 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Noordwest Ziekenhuisgroep
Alkmaar, North Holland, Netherlands, 1815JD